Investor confidence remained high throughout the year, with BioMark's share price maintaining stability and posting modest gains. This performance stands in contrast to the downward trend observed across much of the diagnostics and biotech sectors, highlighting the Company's strategic position and strong fundamentals. "Our team remained focused on disciplined execution, data-driven strategy, and delivering tangible value," said Rashid Bux, BioMark's CEO. "That focus earned us the continued support of invest ...